Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pearl Grimes

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Journal of the American Academy of Dermatology|June 5, 2021
Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trialIltefat Hamzavi, David Rosmarin, John E Harris, et al.
Journal of the American Academy of Dermatology|April 15, 2014
A double-blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scarsJwala Karnik, Leslie Baumann, Suzanne Bruce, et al.
Journal of Drugs in Dermatology : JDD|May 20, 2010
Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgarisEmil Tanghetti, Sunil Dhawan, Lawrence Green, et al.
Lancet (London, England)|July 13, 2020
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trialDavid Rosmarin, Amit G Pandya, Mark Lebwohl, et al.
Dermatology and Therapy|May 5, 2025
Mental Health and Psychosocial Burden Among Patients with Skin of Color Living with Vitiligo: Findings from the Global VALIANT StudyPearl Grimes, Iltefat H Hamzavi, Kristen Bibeau, et al.
The British Journal of Dermatology|July 26, 2023
Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT studyIltefat H Hamzavi, Kristen Bibeau, Pearl Grimes, et al.
Skin Health and Disease|December 3, 2024
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 yearsJohn E Harris, Amit G Pandya, Mark Lebwohl, et al.
The New England Journal of Medicine|October 19, 2022
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for VitiligoDavid Rosmarin, Thierry Passeron, Amit G Pandya, et al.
Journal of the American Academy of Dermatology|April 20, 2010
Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring methodAmit G Pandya, Linda S Hynan, Rafia Bhore, et al.
JAMA Dermatology|August 30, 2023
Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT StudyKristen Bibeau, Khaled Ezzedine, John E Harris, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Journal of the American Academy of Dermatology|June 5, 2021
Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trialIltefat Hamzavi, David Rosmarin, John E Harris, et al.
Journal of the American Academy of Dermatology|April 15, 2014
A double-blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scarsJwala Karnik, Leslie Baumann, Suzanne Bruce, et al.
Journal of Drugs in Dermatology : JDD|May 20, 2010
Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgarisEmil Tanghetti, Sunil Dhawan, Lawrence Green, et al.
Lancet (London, England)|July 13, 2020
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trialDavid Rosmarin, Amit G Pandya, Mark Lebwohl, et al.
Dermatology and Therapy|May 5, 2025
Mental Health and Psychosocial Burden Among Patients with Skin of Color Living with Vitiligo: Findings from the Global VALIANT StudyPearl Grimes, Iltefat H Hamzavi, Kristen Bibeau, et al.
The British Journal of Dermatology|July 26, 2023
Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT studyIltefat H Hamzavi, Kristen Bibeau, Pearl Grimes, et al.
Skin Health and Disease|December 3, 2024
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 yearsJohn E Harris, Amit G Pandya, Mark Lebwohl, et al.
The New England Journal of Medicine|October 19, 2022
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for VitiligoDavid Rosmarin, Thierry Passeron, Amit G Pandya, et al.
Journal of the American Academy of Dermatology|April 20, 2010
Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring methodAmit G Pandya, Linda S Hynan, Rafia Bhore, et al.
JAMA Dermatology|August 30, 2023
Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT StudyKristen Bibeau, Khaled Ezzedine, John E Harris, et al.
Pageof 6